Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion

Journal of Virology

Volumn 90, Issue 19, 2016, Pages 8934-8946

  Ahn, Eunseon ^a   Youngblood, Ben ^b   Lee, Junghwa ^a   Lee, Judong ^a   Sarkar, Surojit ^c,d   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DNA METHYLATION; DOWN REGULATION; EFFECTOR CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UPREGULATION; VIRAL CLEARANCE; BIOSYNTHESIS; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS; METABOLISM; PHYSIOLOGY; PROMOTER REGION;

ADOPTIVE TRANSFER; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROMOTER REGIONS, GENETIC;

EID: 84990203101     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00798-16     Document Type: Article

References (37)

1. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2205-2213. http://dx.doi.org/10.1084/jem.188.12.2205
2. Wherry EJ. 2011. T cell exhaustion. Nat Immunol 12:492-499
3. Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. Cell 138:30-50. http://dx.doi.org/10.1016/j.cell.2009.06.036
4. Jiang Y, Li Y, Zhu B. 2015. T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6:e1792. http://dx.doi.org/10.1038/cddis.2015.162
5. Kim PS, Ahmed R. 2010. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223-230. http://dx.doi.org/10.1016/j.coi.2010.02.005
6. Zou W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274. http://dx.doi.org/10.1038/nrc1586
7. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10:29-37. http://dx.doi.org/10.1038/ni.1679
8. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687. http://dx.doi.org/10.1038/nature04444
9. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354. http://dx.doi.org/10.1038/nature05115
10. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Korman AJ, Lowy I. 2013. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8:e63818. http://dx.doi.org/10.1371/journal.pone.0063818
11. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. 2015. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018-2028. http://dx.doi.org/10.1056/NEJMoa1501824
12. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. 2006. Upregulation of PD-1 expression on HIV-specific CD8+T cells leads to reversible immune dysfunction. Nat Med 12:1198-1202 http://dx.doi.org/10.1038/nm1482
13. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEngl J Med 366:2455-2465. http://dx.doi.org/10.1056/NEJMoa1200694
14. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144. http://dx.doi.org/10.1056/NEJMoa1305133
15. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567. http://dx.doi.org/10.1038/nature14011
16. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562. http://dx.doi.org/10.1038/nature13904
17. Schmidt LH, Kummel A, Gorlich D, Mohr M, Brockling S, Mikesch JH, Grunewald I, Marra A, Schultheis AM, Wardelmann E, Muller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. 2015. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 10:e0136023. http://dx.doi.org/10.1371/journal.pone.0136023
18. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030. http://dx.doi.org/10.1200/JCO.2013.53.0105
19. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670-684. http://dx.doi.org/10.1016/j.immuni.2007.09.006
20. Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, Wherry EJ. 2011. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 12:663-671. http://dx.doi.org/10.1038/ni.2046
21. Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, Ahmed R, Boss JM. 2014. Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med 211:515-527. http://dx.doi.org/10.1084/jem.20130208
22. Oestreich KJ, Yoon H, Ahmed R, Boss JM. 2008. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181:4832-4839. http://dx.doi.org/10.4049/jimmunol.181.7.4832
23. Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ. 2009. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31: 309-320. http://dx.doi.org/10.1016/j.immuni.2009.06.019
24. Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, Cui G, Li MO, Kaech SM. 2014. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41:802-814. http://dx.doi.org/10.1016/j.immuni.2014.10.013
25. Youngblood B, Oestreich KJ, Ha SJ, Duraiswamy J, Akondy RS, West EE, Wei Z, Lu P, Austin JW, Riley JL, Boss JM, Ahmed R. 2011. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 35:400-412. http://dx.doi.org/10.1016/j.immuni.2011.06.015
26. Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, Bordi R, Procopio FA, Miura T, Allen TM, Sidney J, Sette A, Walker BD, Ahmed R, Boss JM, Sekaly RP, Kaufmann DE. 2013. Cutting edge: prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 191:540-544. http://dx.doi.org/10.4049/jimmunol.1203161
27. Masopust D, Vezys V, Marzo AL, Lefrancois L. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413-2417. http://dx.doi.org/10.1126/science.1058867
28. Puglielli MT, Zajac AJ, van der Most RG, Dzuris JL, Sette A, Altman JD, Ahmed R. 2001. In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb. J Virol 75:5099-5107. http://dx.doi.org/10.1128/JVI.75.11.5099-5107.2001
29. Matloubian M, Kolhekar SR, Somasundaram T, Ahmed R. 1993. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J Virol 67:7340-7349
30. Borrow P, Evans CF, Oldstone MB. 1995. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol 69:1059-1070
31. Sevilla N, Kunz S, Holz A, Lewicki H, Homann D, Yamada H, Campbell KP, de La Torre JC, Oldstone MB. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med 192:1249-1260. http://dx.doi.org/10.1084/jem.192.9.1249
32. Mueller SN, Matloubian M, Clemens DM, Sharpe AH, Freeman GJ, Gangappa S, Larsen CP, Ahmed R. 2007. Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc Natl Acad Sci U S A 104:15430-15435. http://dx.doi.org/10.1073/pnas.0702579104
33. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340:207-211. http://dx.doi.org/10.1126/science.1235214
34. Brooks DG, McGavern DB, Oldstone MB. 2006. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest 116:1675-1685. http://dx.doi.org/10.1172/JCI26856
35. Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ. 2012. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol 86:8161-8170. http://dx.doi.org/10.1128/JVI.00889-12
36. Utzschneider DT, Legat A, Fuertes Marraco SA, Carrie L, Luescher I, Speiser DE, Zehn D. 2013. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol 14:603-610. http://dx.doi.org/10.1038/ni.2606
37. Fuse S, Tsai CY, Molloy MJ, Allie SR, Zhang W, Yagita H, Usherwood EJ. 2009. Recall responses by helpless memory CD8+T cells are restricted by the up-regulation of PD-1. J Immunol 182:4244-4254. http://dx.doi.org/10.4049/jimmunol.0802041